- Recommendation ID
- MTG58/1
- Question
Further evidence to address uncertainties about the relative clinical and cost effectiveness of UroLift compared with Rezum, especially in the NHS, would be welcome. This should include:
• exploring long-term clinical outcomes and reintervention rates after UroLift
• assessing the suitability of UroLift for prostates larger than 80 ml and for those with an obstructive median lobe.
- Any explanatory notes
(if applicable) This evidence could be generated by collating UK registry data and including the number of implants used, the length of the procedure and procedural outcomes.
Source guidance details
- Comes from guidance
- UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia
- Number
- MTG58
- Date issued
- May 2021
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/05/2021 |